跳至主要内容
临床试验/JPRN-UMIN000041422
JPRN-UMIN000041422已完成未知

A histological cohort study to assess the safety and effectiveness of olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer - JGOG3026 RESPONSE study

Japanese Gynecologic Oncology Group (JGOG)0 个研究点目标入组 471 人开始时间: 2020年10月27日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
471

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1. platinum-resistant relapsed ovarian cancer 2. stable or progressive disease after platinum-based chemotherapy for patients with platinum-sensitive relapsed ovarian cancer 3. patients who had already received a PARP inhibitor before recurrence 4. patients who received both olaparib and bevacizumab combination maintenance therapy.

研究者

发起方
Japanese Gynecologic Oncology Group (JGOG)

相似试验